{"id":51441,"date":"2025-12-18T22:43:27","date_gmt":"2025-12-18T14:43:27","guid":{"rendered":"https:\/\/flcube.com\/?p=51441"},"modified":"2025-12-18T22:43:29","modified_gmt":"2025-12-18T14:43:29","slug":"asieris-apl-2401-fgfr2-3-inhibitor-wins-nmpa-nod-for-phase-1-solid-tumor-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51441","title":{"rendered":"Asieris\u2019 APL-2401 FGFR2\/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial"},"content":{"rendered":"\n

Jiangsu Asieris Pharmaceuticals Co., Ltd.<\/strong> (SHA: 688176<\/a>) announced that China\u2019s National Medical Products Administration (NMPA) approved a Phase 1 clinical trial<\/strong> for APL-2401 (ASN-8639 tablets)<\/strong>, a highly selective small\u2011molecule dual\u2011target inhibitor of FGFR2\/3<\/strong>, in patients with advanced solid tumors<\/strong> driven by FGFR2\/3 mutations, amplifications, or overexpression.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>18\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>APL-2401 (ASN-8639 tablets)<\/td><\/tr>
Indication<\/strong><\/td>Advanced solid tumors with FGFR2\/3 alterations<\/td><\/tr>
Mechanism<\/strong><\/td>Dual FGFR2\/3 kinase inhibition with tumor microenvironment modulation<\/td><\/tr>
Innovation<\/strong><\/td>First\u2011in\u2011class<\/strong> potential with best\u2011in\u2011class advantages in activity, selectivity, and safety<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>APL-2401<\/th>Competitive Landscape<\/th><\/tr><\/thead>
Targets<\/strong><\/td>FGFR2 and FGFR3 (dual inhibition)<\/td>Single\u2011target FGFR2 or FGFR3 inhibitors lack dual coverage<\/td><\/tr>
Selectivity<\/strong><\/td>Spares FGFR1 and FGFR4<\/strong>, reducing off\u2011target toxicity<\/td>Pan\u2011FGFR inhibitors cause FGFR1\/4\u2011related adverse events<\/td><\/tr>
Preclinical Efficacy<\/strong><\/td>Excellent activity in FGFR2\/3\u2011mutant, amplified, or overexpressed models<\/td>Demonstrates tumor killing and microenvironment modulation<\/td><\/tr>
Safety Margin<\/strong><\/td>Wider therapeutic window vs. pan\u2011FGFR agents<\/td>Lower risk of hyperphosphatemia, retinopathy, and liver toxicity<\/td><\/tr>
Development Status<\/strong><\/td>Phase\u202f1 ready; IND approval in China<\/td>Positioned for rapid global expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
FGFR2\/3 Alteration Prevalence<\/strong><\/td>5\u201110%<\/strong> of solid tumors (bladder, breast, lung, gastric cancers)<\/td>~150,000 eligible patients annually in China<\/td><\/tr>
Global FGFR Market<\/strong><\/td>$1.2\u202fbillion<\/strong> (2025)<\/td>Dominated by pan\u2011FGFR inhibitors (erdafitinib, pemigatinib)<\/td><\/tr>
APL-2401 Peak Sales<\/strong><\/td>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM) by 2032<\/td>25\u201130% share of FGFR2\/3\u2011selective segment<\/td><\/tr>
Competitive Advantage<\/strong><\/td>Dual\u2011target precision<\/strong> with improved safety profile<\/td>Addresses resistance to single\u2011target FGFR inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n